InMed Pharmaceuticals (INM) Depreciation & Amortization - Total (2019 - 2025)
InMed Pharmaceuticals (INM) reported Depreciation & Amortization - Total of $12206.0 for Q2 2025, up 124.37% on a YoY basis from $5440.0 in Q2 2024, and little changed quarter-over-quarter from $12203.0 in Q1 2025.
InMed Pharmaceuticals (INM) Depreciation & Amortization - Total (2019 - 2025) Analysis & Trends
InMed Pharmaceuticals has reported Depreciation & Amortization - Total for 6 years, with the latest figure at $12206.0 in Q2 2025.
- For the quarter ending Q2 2025, Depreciation & Amortization - Total rose 124.37% year-over-year to $12206.0; the trailing twelve-month figure through Mar 2026 stood at $12206.0 (down 71.9% YoY), and the FY2025 full-year result was $50204.0, up 5.16% from the prior year.
- Depreciation & Amortization - Total for Q2 2025 stood at $12206.0, roughly flat from $12203.0 in the prior quarter.
- The five-year high for Depreciation & Amortization - Total was $14242.0 in Q4 2023, with the low at $5440.0 in Q2 2024.
- Historically, Depreciation & Amortization - Total has averaged $11773.0 across 4 years, with a median of $12209.0 in 2024.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization - Total plunged 57.88% — and 2025, when it soared 124.37%.
- InMed Pharmaceuticals' Depreciation & Amortization - Total stood at $8056.0 in 2022, then jumped by 76.79% to $14242.0 in 2023, then retreated by 14.27% to $12209.0 in 2024, then dropped by 0.02% to $12206.0 in 2025.
- The last three Depreciation & Amortization - Total figures came in at $12206.0 (Q2 2025), $12203.0 (Q1 2025), and $12209.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | InMed Pharmaceuticals | 6.00 Mn | 756,271.05 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 12,206.00 |
| Mar 31, 2025 | 12,203.00 |
| Dec 31, 2024 | 12,209.00 |
| Sep 30, 2024 | 13,586.00 |
| Jun 30, 2024 | 5,440.00 |
| Mar 31, 2024 | 14,220.00 |
| Dec 31, 2023 | 14,242.00 |
| Sep 30, 2023 | 13,839.00 |
| Jun 30, 2023 | 12,916.00 |
| Mar 31, 2023 | 10,586.00 |
| Dec 31, 2022 | 8,056.00 |
| Sep 30, 2020 | 21,351.00 |
| Sep 30, 2019 | 7,180.00 |